CClinicalTrials.gg
CompletedNCT03895476Updated Aug 23, 2024Results posted

To Measure Pain Perception Following De-Epithelized Free Gingival Graft Harvesting

An interventional study of palatal wound will be cover with collagen and sutures and palatal wound covered with platelet rich fibrin in Gingival Recession and Palate; Wound, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized clinical comparative study will evaluate the postoperative pain following the FGG graft harvest procedure technique covered by four different methods for coverage of the palatal donor site.

Read the detailed description

This study will compare the application of :

  • hemostatic collagen sponge
  • collagen sponge sealed with abio-adhesive material
  • Platelet rich fibrin
  • physical barrier (stent) on the palatal donor sites with the purpose of which one of these will result in least postoperative pain after epithelialized gingival graft (EGG) harvesting.
02

Conditions studied

  • Gingival Recession
  • Palate; Wound

Browse trials for

03

In context

Gingival Recession

402 studies on the registry are indexed under Gingival Recession; 98 are open to participants now.

This study's enrollment of 72 is above the median of 30 across 368 interventional studies indexed under Gingival Recession.

Browse Gingival Recession studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English speaking
  • At least 18 years old- 70 years old
  • Must be a patient of the UAB Dental School
  • Able to read and understand informed consent document
  • Patients needing soft tissue graft with teeth that have miller class I or II recession (>=2mm) on the facial aspects
  • Presence of periodontally healthy teeth at the recipient site.
  • Ability of the participants to maintain good oral hygiene
  • Patient not pregnant or breastfeeding
  • Not taking medications known to cause gingival enlargement

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
  • Less than 18 years old, older than 70 years old
  • Smokers/tobacco users
  • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
  • Patients that have severe gingival recession (Miller class III and IV) or \< 2 mm.
  • Presence of periodontal disease at the recipient site.
  • Poor oral hygiene
  • Patient pregnant or breastfeeding
  • Taking medications known to cause gingival enlargement
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    Collagen Plug with sutures

    Palatal wound will be protected with collagen plug and sutures.

    Diagnostic Test: palatal wound will be cover with collagen and sutures

  • Active comparator
    Platelet Rich Fibrin (PRF)

    palatal wound will be protected with Platelet rich Fibrin

    Diagnostic Test: palatal wound covered with platelet rich fibrin

  • Active comparator
    Collagen Plug with Cyanoacrylate (CPC)

    Palatal wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.

    Diagnostic Test: palatal wound covered with a collagen sponge and cyanoacrylate

  • Active comparator
    Palatal Stent

    Palatal wound will be protected with palatal stent.

    Diagnostic Test: palatal wound covered with a stent

Interventions

  • Diagnostic testpalatal wound will be cover with collagen and sutures

    after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site

  • Diagnostic testpalatal wound covered with platelet rich fibrin

    after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site

  • Diagnostic testpalatal wound covered with a collagen sponge and cyanoacrylate

    after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position

  • Diagnostic testpalatal wound covered with a stent

    after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound

06

What researchers measure

Primary outcomes

  1. Pain Assessment (0=No Pain to 10=Worst)

    To assess the pain outcomes using the visual analog scale from 0=No pain to 10=worst, excrutiating pain. Assessed daily from days 1 to 14, Day 14 reported.

    Time frame: day 14

  2. Bleeding Assessment

    To assessed the bleeding outcomes using the visual analog scale (VAS) from 0=No bruising/bleeding to 10=severe bruising/bleeding. Assessed daily from days 1 to 14, Day 14 reported.

    Time frame: day 14

Secondary outcomes

  1. Activity Tolerance

    To assess the effects on daily activities using the visual analog scale from 0=No Limitation to 10= Bedrest required. Assessed daily from days 1 to 14, Day 14 reported.

    Time frame: day 14

  2. Amount of Swelling

    To assessed the swelling outcomes using the visual scale (VAS) from 0=No swelling to 10=severe swelling. Assessed daily from days 1 to 14, Day 14 reported.

    Time frame: day 14

  3. The Need for Painkiller

    To assess the needs for the painkiller using the visual analog scale (VAS). (0 = No painkiller needed to 10 = Needed painkiller). Assessed daily from days 1 to 14, Day 14 reported.

    Time frame: day 14

07

Results

Posted Aug 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
Started18181818
Completed18181818
Not completed0000

Outcome measures

PrimaryPain Assessment (0=No Pain to 10=Worst)

To assess the pain outcomes using the visual analog scale from 0=No pain to 10=worst, excrutiating pain. Assessed daily from days 1 to 14, Day 14 reported.

Time frame:
day 14
Reported as:
Mean · score on a scale
Pain Assessment (0=No Pain to 10=Worst)
score on a scaleCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
Pain Assessment (0=No Pain to 10=Worst)4.2 ± 2.41.9 ± 2.12.2 ± 2.51 ± 1.4
PrimaryBleeding Assessment

To assessed the bleeding outcomes using the visual analog scale (VAS) from 0=No bruising/bleeding to 10=severe bruising/bleeding. Assessed daily from days 1 to 14, Day 14 reported.

Time frame:
day 14
Reported as:
Mean · score on a scale
Bleeding Assessment
score on a scaleCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
Bleeding Assessment1 ± 1.90.6 ± 1.40.9 ± 1.90.7 ± 1.6
SecondaryActivity Tolerance

To assess the effects on daily activities using the visual analog scale from 0=No Limitation to 10= Bedrest required. Assessed daily from days 1 to 14, Day 14 reported.

Time frame:
day 14
Reported as:
Mean · score on a scale
Activity Tolerance
score on a scaleCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
Activity Tolerance2.4 ± 2.41.5 ± 2.11.8 ± 2.41.3 ± 1.8
SecondaryAmount of Swelling

To assessed the swelling outcomes using the visual scale (VAS) from 0=No swelling to 10=severe swelling. Assessed daily from days 1 to 14, Day 14 reported.

Time frame:
day 14
Reported as:
Mean · score on a scale
Amount of Swelling
score on a scaleCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
Amount of Swelling2.2 ± 2.41.3 ± 1.91.4 ± 21.3 ± 2
SecondaryThe Need for Painkiller

To assess the needs for the painkiller using the visual analog scale (VAS). (0 = No painkiller needed to 10 = Needed painkiller). Assessed daily from days 1 to 14, Day 14 reported.

Time frame:
day 14
Reported as:
Mean · score on a scale
The Need for Painkiller
score on a scaleCollagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal Stent
The Need for Painkiller2.1 ± 2.52 ± 2.62.2 ± 2.81.5 ± 1.8

Adverse events

Collected over 14 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Collagen Plug With Sutures0/18 (0%)0/18 (0%)0/18 (0%)
Platelet Rich Fibrin (PRF)0/18 (0%)0/18 (0%)0/18 (0%)
Collagen Plug With Cyanoacrylate (CPC)0/18 (0%)0/18 (0%)0/18 (0%)
Palatal Stent0/18 (0%)0/18 (0%)0/18 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Collagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal StentTotal
<=18 years10001
Between 18 and 65 years106151243
>=65 years7123628
Sex: Female, Male
Sex: Female, Male(Participants)Collagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal StentTotal
Female1114101045
Male748827
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Collagen Plug With SuturesPlatelet Rich Fibrin (PRF)Collagen Plug With Cyanoacrylate (CPC)Palatal StentTotal
American Indian or Alaska Native00000
Asian00022
Native Hawaiian or Other Pacific Islander00000
Black or African American11215
White1717161565
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Unversity of Alabama at Birmingham, School of Dentistry
    Birmingham, Alabama 35294-0007, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 23, 2023

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03895476
Lead sponsor
University of Alabama at Birmingham
Responsible party
Hussein Basma (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Mar 29, 2019
Start date
Jun 8, 2020
Primary completion
Jul 30, 2021
Completion
Feb 27, 2023
Results posted
Aug 23, 2024
Last update
Aug 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion